Equities

Pharma-Bio Serv Inc

PBSV:QBB

Pharma-Bio Serv Inc

Actions
  • Price (USD)0.5818
  • Today's Change0.00 / 0.00%
  • Shares traded60.00
  • 1 Year change-34.99%
  • Beta0.5755
Data delayed at least 15 minutes, as of Sep 20 2024 18:24 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Pharma-Bio Serv Inc had revenues fall -12.48% from 19.40m to 16.98m, though the company grew net income 30.15% from 1.01m to 1.31m.
Gross margin28.10%
Net profit margin-0.04%
Operating margin-2.65%
Return on assets-0.03%
Return on equity-0.04%
Return on investment-0.03%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Pharma-Bio Serv Inc fell by 4.02m. However, the company earned 1.89m from its operations for a Cash Flow Margin of 11.14%. In addition the company used 4.22m on investing activities and also paid 1.76m in financing cash flows.
Cash flow per share0.0011
Price/Cash flow per share510.98
Book value per share0.6077
Tangible book value per share0.6077
More ▼

Balance sheet in USDView more

Pharma-Bio Serv Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio7.52
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 30.34%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)-1.76
EPS (TTM) vs
TTM 1 year ago
-100.44
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.